251 related articles for article (PubMed ID: 36270561)
1. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J; Lafayette R; Kristensen J; Stone A; Cattran D; Floege J; Tesar V; Trimarchi H; Zhang H; Eren N; Paliege A; Rovin BH;
Kidney Int; 2023 Feb; 103(2):391-402. PubMed ID: 36270561
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J;
Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292
[TBL] [Abstract][Full Text] [Related]
3. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
[TBL] [Abstract][Full Text] [Related]
4. A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide.
Antonucci L; Colucci M; Emma F; Vivarelli M
Pediatr Nephrol; 2023 Nov; 38(11):3849-3852. PubMed ID: 37041389
[TBL] [Abstract][Full Text] [Related]
5. A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond.
Coppo R
Kidney Int; 2023 Feb; 103(2):258-261. PubMed ID: 36681455
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Barratt J; Liew A; Yeo SC; Fernström A; Barbour SJ; Sperati CJ; Villanueva R; Wu MJ; Wang D; Borodovsky A; Badri P; Yureneva E; Bhan I; Cattran D;
Clin J Am Soc Nephrol; 2024 Apr; 19(4):452-462. PubMed ID: 38214599
[TBL] [Abstract][Full Text] [Related]
9. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
10. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
Ramjee L; Vurgun N; Ngai C; Patel M; Tremblay G
Clinicoecon Outcomes Res; 2023; 15():213-226. PubMed ID: 37020570
[TBL] [Abstract][Full Text] [Related]
12. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy.
Barratt J; Lafayette RA; Rovin BH; Fellström B
Expert Rev Clin Immunol; 2023; 19(7):699-710. PubMed ID: 37103889
[TBL] [Abstract][Full Text] [Related]
13. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.
Smerud HK; Bárány P; Lindström K; Fernström A; Sandell A; Påhlsson P; Fellström B
Nephrol Dial Transplant; 2011 Oct; 26(10):3237-42. PubMed ID: 21378156
[TBL] [Abstract][Full Text] [Related]
14. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J
Kidney Int; 2024 Jan; 105(1):189-199. PubMed ID: 37914086
[TBL] [Abstract][Full Text] [Related]
15. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V;
JAMA; 2017 Aug; 318(5):432-442. PubMed ID: 28763548
[TBL] [Abstract][Full Text] [Related]
16. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
[TBL] [Abstract][Full Text] [Related]
17. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
Am J Nephrol; 2021; 52(10-11):827-836. PubMed ID: 34731857
[TBL] [Abstract][Full Text] [Related]
18. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J; Wong MG; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Jardine MJ; Reich HN; Cattran D; Glassock R; Levin A; Wheeler DC; Woodward M; Billot L; Stepien S; Rogers K; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
JAMA; 2022 May; 327(19):1888-1898. PubMed ID: 35579642
[TBL] [Abstract][Full Text] [Related]
19. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.
Liao J; Zhou Y; Xu X; Huang K; Chen P; Wu Y; Jin B; Hu Q; Chen G; Zhao S
Front Immunol; 2022; 13():926517. PubMed ID: 36685528
[TBL] [Abstract][Full Text] [Related]
20. An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression.
Obrișcă B; Vornicu A; Mocanu V; Dimofte G; Andronesi A; Bobeică R; Jurubiță R; Sorohan B; Caceaune N; Ismail G
Sci Rep; 2023 Nov; 13(1):20119. PubMed ID: 37978255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
